Cancer Prevention
Reports add new data to cancer prevention research
Published in Hepatitis Weekly, December 12th, 2005
Study 1: Long-term interferon (IFN) therapy for chronic hepatitis C prevents liver cancer.
"Effect of IFN therapy for refractory chronic hepatitis C is not sufficient. For patients with persistent hepatitis C virus (HCV) infection, one of the clinical goals is prevention of progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC)," scientists in Japan report.
"In this study, we evaluated the effect of long-term IFN administration for refractory chronic hepatitis C. The patients who were positive for HCV of genotype 1b in high viral load and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-12-12)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
Extracorporal liver support shows promise in hepatitis B-associated hepatic failure - Hepatitis D Virus
Hepatitis delta virus RNA genome evolution occurs during long-term replication - Hepatitis Therapy
Glucocerebroside treatment ameliorates ConA hepatitis - Hepatitis Vaccine
Anti-phospholipid antibodies are produced using recombinant hepatitis B vaccine - Hepatitis Vaccine
Insert position, C terminus, and epitope sequence are relevant in vaccine design - Cancer Therapy
Interferon treatment increases virotherapy for advanced hepatocellular carcinoma - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
